Evidence map›Paper›PMID 40089712›Full record

ArticleBMC pulmonary medicine2025

Risk prediction and early intervention strategies for persistent SARS-CoV-2 infection in patients with non-Hodgkin lymphoma: a retrospective cohort study.

Wailong Zou, Jia Zhang, Yulin Li, Yuwei Cao, Jiaxin Li, Zhe Zhang, Xin Zhang, Chuan Song, Rui Yang, Yaxin Yan and 4 more

Abstract readEvaluation Study
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wailong ZouDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Jia ZhangDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Yulin LiDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Yuwei CaoDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Jiaxin LiDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Zhe ZhangDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Xin ZhangDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Chuan SongDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Rui YangDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Yaxin YanDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Yumin WangDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Xinjun ZhangDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Zhe XuDepartment of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, China. 15301050459@163.com.
Jichao ChenDepartment of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China. 604939512@qq.com.

Funding

National Natural Science Foundation of China 82300089
6 · The paper itself

Abstract

backgroundPatients with non-Hodgkin lymphoma (NHL) face heightened mortality and accelerated disease progression when persistently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This critical situation underscores the urgent need to identify risk factors and establish early intervention strategies tailored to this vulnerable population. The primary aim of this study was to investigate the risk factors associated with persistent SARS-CoV-2 infection in NHL patients during the COVID-19 pandemic.

methodsA retrospective cohort study was conducted using data from January 2020 to June 2024, obtained from the Aerospace Center Hospital's database, electronic health records, and laboratory archives. Inclusion criteria comprised patients with confirmed NHL and SARS-CoV-2 infection, with persistence defined as positive viral test results beyond 14 days after initial diagnosis. Patients with incomplete medical records or loss of follow-up were excluded. Predictive models were developed and refined using logistic regression and random forest algorithms. The models incorporated data on demographics, comorbidities, laboratory findings, and imaging results. Model performance was evaluated using accuracy, precision, and the area under the receiver operating characteristic curve (AUC-ROC). Validation was conducted on an independent dataset to ensure generalizability, and the best-performing model guided the development of a prediction tool for early risk assessment and intervention.

resultsKey risk factors for persistent SARS-CoV-2 infection in NHL patients included advanced age, hypertension, diabetes, immunosuppressed status, low lymphocyte count, elevated C-reactive protein, high body mass index, anemia, reduced CD4 + cell count, and the presence of lung lesions. The random forest model demonstrated superior predictive performance, achieving an AUC of 0.93. The study further highlighted that prompt antiviral therapy, adjustments to immunosuppressive regimens, and enhanced monitoring significantly reduced infection persistence.

conclusionsThis study identifies critical risk factors for persistent SARS-CoV-2 infection in NHL patients and underscores the importance of early intervention strategies. These findings may guide clinical decision-making to improve outcomes in this high-risk population.

Indexed as

Clinical Decision RulesCOVID-19COVID-19 Drug TreatmentLymphoma, Non-HodgkinRisk AssessmentSARS-CoV-2AdultAgedArea Under CurveComorbidityDatabases, FactualFemaleHumansLogistic ModelsMaleMiddle AgedNon-Hodgkin’s lymphomaPersistent SARS-CoV-2 infectionRisk factors

Identifiers

PMID40089712
PMCPMC11910862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.